![]() Immatics Immatics is a biotechnology company that is primarily engaged in the research and development of T cell redirecting immunotherapies for the treatment of cancer. | ![]() MABION Mabion is a biotechnology company engaged in research and development of biotechnology and biosimilar drugs to treat cancer, autoimmune, and metabolic diseases. | ![]() Lion TCR Lion TCR is a clinical-stage biotechnology company that develops TCR-T cell therapy for cancers and life-threatening infectious diseases. | ||
Founding Date | Founding Date N/A | Founding Date 2007 | Founding Date N/A | Founding Date 2018 |
Type | Type Public | Type Public | Type Private | Type Private |
Tags | ||||
Locations | Locations Tübingen, DE HQ Frankfurt Am Main, DE München, DE Houston, US | Locations Konstantynów Łódzki, PL HQ | Locations Singapore, SG HQ Guangzhou, CN Singapore, SG Singapore, SG | Locations Waltham, US HQ Shanghai, CN Boston, US |
Employees | Employees 29723% increase | Employees 95 | Employees N/A | Employees 8 |
Valuation ($) | Valuation ($) 1.1 b | Valuation ($) 21.7 m | Valuation ($) N/A | Valuation ($) N/A |
Financial | ||||
Revenue (est.) | Revenue (est.) €48.3m (FY, 2025) | Revenue (est.) zł15.8m (FY, 2025) | Revenue (est.) N/A | Revenue (est.) N/A |
Cost of goods | Cost of goods N/A | Cost of goods zł24.1m (FY, 2025) | Cost of goods N/A | Cost of goods N/A |
Gross profit | Gross profit €53m (FY, 2025) | Gross profit (zł7.2m) (FY, 2025) | Gross profit N/A | Gross profit N/A |
Net income | Net income (€196.4m) (FY, 2025) | Net income (zł62.6m) (FY, 2025) | Net income N/A | Net income N/A |
Funding | ||||
Latest funding round | Latest funding round N/A | Latest funding round N/A | Latest funding round $ 20m (about 8 years ago) | Latest funding round $ 80m (about 7 years ago) |
Total funding raised | Total funding raised $ 267.3m | Total funding raised N/A | Total funding raised $ 20m | Total funding raised $ 96.5m |

Mabion is a biotechnology company engaged in research and development of biotechnology and biosimilar drugs to treat cancer, autoimmune, and metabolic diseases.
View company
Lion TCR is a clinical-stage biotechnology company that develops TCR-T cell therapy for cancers and life-threatening infectious diseases.
View company